Add to ORKGSummary Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost-effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost-effective, particularly for patients at high risk of fracture and low adherence to oral treatments. Introduction Denosumab is a novel biologic agent devel-oped for the treatment of osteoporosis and osteoporotic fractures that has been shown to reduce the risk of fractures in a phase III trial. The objective of this study was to estimate the cost-effectiveness of denosumab from
Background: We aimed to review the systematic economic evaluation of denosumab versus than alternati...
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor...
Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creati...
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate th...
Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...
Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...
Summary: The objective was to undertake a health economic analysis of denosumab for the treatment of...
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosum...
Denosumab has recently been shown to be safe and to significantly reduce the risk of vertebral, hip ...
Summary: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic ...
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeleta...
Copyright © 2014 Chiara de Waure et al. This is an open access article distributed under the Creativ...
Introduction. Bone mass loss (BML) is one of the adverse effects of oncological chemotherapy, especi...
Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related...
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevent...
Background: We aimed to review the systematic economic evaluation of denosumab versus than alternati...
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor...
Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creati...
Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate th...
Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...
Denosumab is a novel biological agent for the treatment of osteoporosis in postmenopausal women with...
Summary: The objective was to undertake a health economic analysis of denosumab for the treatment of...
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of denosum...
Denosumab has recently been shown to be safe and to significantly reduce the risk of vertebral, hip ...
Summary: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic ...
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeleta...
Copyright © 2014 Chiara de Waure et al. This is an open access article distributed under the Creativ...
Introduction. Bone mass loss (BML) is one of the adverse effects of oncological chemotherapy, especi...
Aim: The approved indication for denosumab (120 mg) was expanded in 2018 to include skeletal-related...
The objective of this study was to estimate the cost-effectiveness of denosumab for fracture prevent...
Background: We aimed to review the systematic economic evaluation of denosumab versus than alternati...
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor...
Copyright © 2015 Stuart Silverman et al. This is an open access article distributed under the Creati...